Quantcast

Latest Debiopharm Stories

2014-09-30 08:32:22

Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing...

2014-09-26 04:21:25

LAUSANNE, Switzerland, September 26, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs and companion diagnostics for personalized medicine, will be presenting the 'JCA-Mauvernay Award' on September 27 to Doctors Eiji Hara from the Japanese Foundation for Cancer Research for his basic research on Cellular senescence and cancer: a gut microbial connection and...

2014-09-04 08:30:00

LAUSANNE, Switzerland, September 4, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute...

2014-06-24 12:28:27

LAUSANNE, Switzerland and KOLKATA, India, June 24, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including anti-bacterial, oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced that they have...

2014-06-19 04:21:30

LAUSANNE, Switzerland, June 19, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known...

2014-05-28 08:31:42

LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual...

2014-05-27 04:21:40

SINGAPORE and LAUSANNE, Switzerland, May 27, 2014 /PRNewswire/ -- Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines with a strong sales network of 360 dedicated and experienced sales representatives and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet...

2014-05-06 04:23:26

LAUSANNE, Switzerland, May 6, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and...

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-04-02 04:21:07

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects - Evotec and Debiopharm to share discovery and development efforts Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne, Switzerland. The objective of this collaboration is to identify and...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related